FDA Looks to Expand Availability of Biosimilars in Bid to Lower Drug Costs
- October 31, 2025
The Food and Drug Administration (FDA) wants to streamline the process for approving new biosimilars as potential lower-cost alternatives to pricey biologics, according to draft guidance issued October 29.
ARTICLE TAGS
You must be logged in to access this content.